We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SPHL:NASDAQSpringview Holdings Ltd Analysis

Data as of 2026-06-06 - not real-time

$5.35

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Springview Holdings is trading at $5.35, well above its 20‑day SMA of $2.74 and 50‑day SMA of $2.63, yet still far below the 200‑day SMA of $3.54, indicating a short‑term price surge that lacks long‑term support. The technical picture is mixed: a bullish MACD histogram (+0.17) and a very high RSI of 83 suggest strong upward momentum but also signal that the stock is in overbought territory. Volatility is extreme, with a 30‑day swing of roughly 248% and a historic max drawdown of –87%, underscoring the risk of rapid price reversals. Fundamentals are weak – the company posts negative operating (‑48%) and profit margins (‑30%), negative cash flows, and a price‑to‑book of 13.9, implying the market is pricing in significant growth expectations despite poor earnings.
Recent news adds a layer of uncertainty: the firm secured a major heritage redevelopment contract in Singapore, which could provide a catalyst for revenue, but it also received a Nasdaq notice concerning minimum bid requirements, raising potential compliance concerns. Investors should weigh the short‑term technical upside against the deep‑seated financial weaknesses and heightened volatility before deciding on exposure.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • RSI in overbought territory
  • Extreme 30‑day volatility
  • Negative earnings and cash flow

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential revenue uplift from new heritage contract
  • Continued earnings pressure
  • High price‑to‑book ratio

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Fundamental turnaround required
  • Sector cyclicality may eventually support demand
  • Regulatory and compliance uncertainties

Key Metrics & Analysis

Financial Health

Revenue Growth5.80%
Profit Margin-30.13%
ROE-35.42%
ROA-13.99%
Debt/Equity15.28
P/B Ratio13.9
Op. Cash Flow$-2039992
Free Cash Flow$-2355800

Technical Analysis

TrendNeutral
RSI83.3
Support$2.30
Resistance$10.71
MA 20$2.74
MA 50$2.63
MA 200$3.54
MACDBullish
VolumeIncreasing
Fear & Greed Index83.02

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta-0.23
Volatility248.28%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.